Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Taysha Gene Therapies announced that its Compensation Committee granted stock options to three new employees on November 1, 2024. The options allow the purchase of 157,000 shares of common stock at $1.53 per share, matching the closing price on the grant date. These options were granted under the company's 2023 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies will present biodistribution data from an analysis of 28 non-human primates (NHPs) at the 31st Annual ESGCT Congress in Rome. The analysis, spanning five studies, evaluated AAV9 gene therapy vector delivery using intrathecal (IT) and intra-cisterna magna (ICM) administration.
Key findings include:
- Lumbar IT administration led to widespread and consistent biodistribution across brain and spinal cord regions
- IT and ICM administration achieved comparable biodistribution in NHPs
- Results support IT administration as an effective, safe, and minimally invasive approach for delivering AAV-based gene therapies for CNS diseases in children and adults
The data reinforces Taysha's clinical development strategy, particularly for their TSHA-102 program targeting Rett syndrome. The poster presentation, titled 'Broad CNS Biodistribution of AAV9-based Gene Therapies Delivered by Intrathecal Lumbar Puncture in Non-Human Primates,' will be presented on October 23, 2024.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted a new employee an option to purchase 501,600 shares of the company's common stock.
The stock option, granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan, has an exercise price of $2.02 per share, equal to the closing price on the grant date. It has a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service.
Taysha Gene Therapies (Nasdaq: TSHA) announced an upcoming oral presentation at the 9th World Rett Syndrome Congress in Queensland, Australia, from October 2-5, 2024. The presentation will cover previously disclosed clinical data on the TSHA-102 program for Rett syndrome, including:
1. Positive clinical data up to 52 weeks from the ongoing REVEAL Phase 1/2 adolescent and adult trial
2. Initial clinical data up to 22 weeks from the REVEAL Phase 1/2 pediatric trial
The company expects to provide additional clinical data in the first half of 2025, including:
- Cohort two (high dose, n=3) results
- Longer-term update on cohort one (low dose, n=2) from both trials
The presentation, titled 'First cohort data from the REVEAL adolescent/adult and pediatric studies of TSHA-102 gene therapy for Rett syndrome,' will be given by Dr. Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies.
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On September 3, 2024, the company's Compensation Committee granted a new employee an option to purchase 311,000 shares of common stock. The stock option, issued under Taysha's 2023 Inducement Plan, has an exercise price of $2.06 per share, equal to the closing price on the grant date. The option has a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Presented encouraging data from TSHA-102 trials for Rett syndrome in adult and pediatric patients
- Dosed first patient in high-dose cohort of adolescent/adult trial with no serious adverse events
- Raised $76.8 million in June 2024 offering, extending cash runway into Q4 2026
- Q2 2024 net loss of $20.9 million ($0.09 per share)
- Cash and equivalents of $172.7 million as of June 30, 2024
The company plans to report clinical data from high-dose cohorts and update on low-dose cohorts for both REVEAL trials in 1H 2025.
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for severe monogenic CNS diseases, has announced its plans to release second quarter 2024 financial results and host a corporate update conference call on August 12, 2024. The event is scheduled for 8:30 AM Eastern Time.
Investors and interested parties can access the conference call via toll-free and international numbers, or join the webcast through the company's investor relations website. This upcoming financial disclosure and corporate update will provide insights into Taysha's performance and progress in developing gene therapies for CNS disorders.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focusing on AAV-based gene therapies for CNS diseases, has announced the granting of stock options to two new employees. The Compensation Committee approved options to purchase 356,000 shares of common stock on August 1, 2024, under the company's 2023 Inducement Plan. These options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), have an exercise price of $2.16 per share, equal to the closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (TSHA) has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On July 3, 2024, the Compensation Committee granted four new employees options to purchase a total of 484,000 shares of the company's common stock. The options were issued under the 2023 Inducement Plan to encourage the new hires, with an exercise price of $2.15 per share, matching the closing price on the grant date. These options have a 10-year term and follow a four-year vesting schedule—25% vest on the first anniversary of the vesting start date, with the remaining 75% vesting in equal monthly installments over the next three years, contingent on continuous service.
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for severe CNS diseases, has announced the pricing of its public offering. The offering includes 14,361,113 shares of common stock at $2.25 per share and pre-funded warrants for 18,972,221 shares at $2.249 per warrant. Gross proceeds are expected to be approximately $75 million before underwriting discounts and expenses. An additional 15% of shares may be available to underwriters within 30 days. The offering is set to close around June 27, 2024, pending usual conditions. Jefferies and Goldman Sachs are the lead book-running managers, with Cantor also participating.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
